Valuation : GlaxoSmithKline Pakistan Limited

Market Cap 99.78B 360M 310M 292M 266M 497M 34.26B 499M 3.46B 1.34B 17.45B 1.35B 1.32B 55.29B P/E 2026 *
9.43x
P/E 2027 * 7.84x
Enterprise Value 99.78B 360M 310M 292M 266M 497M 34.26B 499M 3.46B 1.34B 17.45B 1.35B 1.32B 55.29B EV / Sales 2026 *
1.45x
EV / Sales 2027 * 1.34x
Free-Float
16.89%
Yield 2026 *
5.76%
Yield 2027 * 6.64%
09-03 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Chief Financial Officer, Effective October 15, 2026 CI
09-03 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Finance Director, Effective October 15, 2026 CI
08-28 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
08-25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-25 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026 CI
08-02 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
08-02 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
05-31 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
04-27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day-0.42%
1 week-3.80%
Current month-6.46%
1 month-10.21%
3 months-9.62%
6 months+6.90%
Current year-19.62%
1 week 312.06
Extreme 312.06
325
1 month 312.06
Extreme 312.06
349.99
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 69.21
Extreme 69.21
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 2020-02-29
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2011-05-06
Director/Board Member - 2018-12-04
Director/Board Member 72 2020-04-01
Change 5-day change 1-year change 3-year change Capi.($)
-0.42%-3.80%-22.85%+341.30% 360M
+0.03%-3.09%+49.77%+91.69% 1,002B
-0.76%-2.95%+50.93%+66.34% 644B
+0.86%-4.13%+19.24%+68.37% 443B
-0.80%-0.43%+28.92%+35.45% 343B
-0.13%-14.97%+9.41%+26.71% 262B
-1.90%-2.72%-2.72%+7.41% 245B
-0.48%-11.65%+39.75%+50.82% 212B
-1.06%-4.23%-14.70%-57.36% 199B
-0.68%-2.65%+25.82%+91.64% 181B
Average -0.55%-4.80%+18.36%+72.24% 353B
Weighted average by Cap. -0.42%-4.24%+32.02%+57.19%

Financials

2026 *2027 *
Net sales 68.81B 248M 214M 201M 183M 343M 23.62B 344M 2.38B 921M 12.04B 932M 912M 38.13B 74.58B 269M 232M 218M 199M 372M 25.6B 373M 2.58B 999M 13.04B 1.01B 988M 41.32B
Net income 10.49B 37.85M 32.57M 30.66M 27.94M 52.28M 3.6B 52.48M 363M 140M 1.83B 142M 139M 5.81B 12.42B 44.81M 38.56M 36.31M 33.08M 61.9M 4.26B 62.14M 430M 166M 2.17B 168M 165M 6.88B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
26-09-09 PKR 313.32 -0.42% 62,993
26-09-08 PKR 314.64 -1.87% 210,309
26-09-07 PKR 320.62 -0.74% 80,168
26-09-04 PKR 323.01 -0.02% 122,258
26-09-03 PKR 323.08 -0.80% 118,223
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
313.32PKR
Average target price
510.00PKR
Spread / Average Target
+62.77%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!